株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:骨髄線維症

Market Spotlight: Myelofibrosis

発行 Datamonitor Healthcare 商品コード 573560
出版日 ページ情報 英文 44 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=108.54円で換算しております。
注目市場の分析:骨髄線維症 Market Spotlight: Myelofibrosis
出版日: 2020年01月10日 ページ情報: 英文 44 Pages
概要

世界の50歳以上の人口における骨髄線維症の有病数は、2016年の46,000人から、2025年には57,000人に増加すると予測されています。

当レポートでは、世界の骨髄線維症の市場を調査し、疾患の背景・概要、有病者数の10カ年予測、パイプライン薬および上市済み薬剤の概要、臨床試験の状況、ライセンシング・資産買収などの主要取引の動向、特許情報、主要薬剤の収益予測などをまとめています。

要点

疾患の背景

  • 分類

治療

  • 貧血
  • 脾腫
  • 根治療法

疫学

パイプライン薬

上市済み薬剤

今後の主な予定

主な法規制関連の出来事

ライセンシング・資産買収などの取引

親特許

収益機会

臨床試験環境

文献

付録

目次
Product Code: DMKC0179494

Myelofibrosis is a myeloproliferative neoplasm which can exist as a primary disease known as primary myelofibrosis, or can evolve to post- polycythemia vera (PV) or post-essential thrombocythemia (ET) myelofibrosis from PV or ET. It is characterized by the buildup of scar tissue (fibrosis) in bone marrow, which leads to a reduction in blood cell production.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 47,000 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 58,300 prevalent cases by 2026. The global prevalence of myelofibrosis is estimated to be 0.0027%. Bristol-Myers Squibb's Inrebic and Incyte's Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.

The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II. Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.

High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib and momelotinib.

The overall likelihood of approval of a Phase I hematologic asset is 9.9%, and the average probability a drug advances from Phase III is 59.4%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been only three licensing and asset acquisition deals involving myelofibrosis drugs during 2015-20. The largest deal was the $1,250m agreement in 2015 between Bristol-Myers Squibb and Promedior, pursuant to which Bristol-Myers Squibb was granted an exclusive right to acquire Promedior along with its lead asset PRM-151, which is in development for idiopathic pulmonary fibrosis and myelofibrosis.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for myelofibrosis have been in the early and mid-phases of development, with 86% of trials in Phase I-II, and only 14% in Phase III-IV.

The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major EU markets, while Israel has the top spot in Asia.

Novartis has the highest number of completed clinical trials for myelofibrosis, with 15 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Anemia
  • Splenomegaly
  • Curative treatment

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Reblozyl for Myelofibrosis (November 6, 2019)
  • Pracinostat for Myelofibrosis (July 31, 2019)
  • CPI-0610 for Myelofibrosis (June 3, 2019)
  • Inrebic for Myelofibrosis (June 3, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol
  • Celgene Takes Important Regulatory Step Ahead Of Bristol Merger With Fedratinib Filing
  • Pacritinib MAA Withdrawal
  • Patients Speak Up On Pacritinib

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Roche Paying $390m Up Front For Fibrosis-Fighting Promedior
  • Deals Shaping The Medical Industry, January 2019

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of myelofibrosis, 2017-26
  • Figure 2: Overview of pipeline drugs for myelofibrosis in the US
  • Figure 3: Pipeline drugs for myelofibrosis, by company
  • Figure 4: Pipeline drugs for myelofibrosis, by drug type
  • Figure 5: Pipeline drugs for myelofibrosis, by classification
  • Figure 6: Reblozyl for Myelofibrosis (November 6, 2019): Phase II - MF-001
  • Figure 7: CPI-0610 for Myelofibrosis (June 3, 2019): Phase I/II - MANIFEST (+/- Ruxolitinib)
  • Figure 8: Key upcoming events in myelofibrosis
  • Figure 9: Probability of success in the myelofibrosis pipeline
  • Figure 10: Licensing and asset acquisition deals in myelofibrosis, 2015-20
  • Figure 11: Parent patents in myelofibrosis
  • Figure 12: Clinical trials in myelofibrosis
  • Figure 13: Top 10 drugs for clinical trials in myelofibrosis
  • Figure 14: Top 10 companies for clinical trials in myelofibrosis
  • Figure 15: Trial locations in myelofibrosis
  • Figure 16: Myelofibrosis trials status
  • Figure 17: Myelofibrosis trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of myelofibrosis, 2017-26
  • Table 2: Marketed drugs for myelofibrosis
  • Table 3: Pipeline drugs for myelofibrosis in the US
  • Table 4: Reblozyl for Myelofibrosis (November 6, 2019)
  • Table 5: Pracinostat for Myelofibrosis (July 31, 2019)
  • Table 6: CPI-0610 for Myelofibrosis (June 3, 2019)
  • Table 7: Inrebic for Myelofibrosis (June 3, 2019)
  • Table 8: Historical global sales, by drug ($m), 2014-18
  • Table 9: Forecasted global sales, by drug ($m), 2020-24